2025 Year in Review
The pharmaceutical landscape is evolving rapidly, driven by the arrival of innovative new treatments and the growing impact of chronic diseases. To better understand the key elements influencing drug insurance plans, this is an overview of the trends observed at Desjardins Insurance.
The following data were observed in 2025. They illustrate where spending is concentrated by drug, age group, sex, and therapeutic class. This analysis highlights the most common health conditions, the adoption of new treatments, and the factors shaping cost dynamics within group insurance.
The pharmaceutical landscape is evolving rapidly, driven by the arrival of innovative new treatments and the growing impact of chronic diseases. To better understand the key elements influencing drug insurance plans, this is an overview of the trends observed at Desjardins Insurance.
The following data were observed in 2025. They illustrate where spending is concentrated by drug, age group, sex, and therapeutic class. This analysis highlights the most common health conditions, the adoption of new treatments, and the factors shaping cost dynamics within group insurance.
Methodology
This trend analysis is based on all drug insurance claim data from Desjardins Insurance for the year 2025. Results reflect the amounts paid, excluding the amount paid by insureds (deductibles and coinsurance).
The studied population includes insured persons covered by group insurance plans administered by Desjardins Insurance during the period in scope. The analyses are based on administrative claims data, which do not directly reflect clinical diagnoses made by healthcare professionals.
Spending was aggregated and analyzed along several dimensions:
- by brand name drugs to observe product-specifc trends, or by brand name drugs and their generics for a broader view
- by therapeutic class
- by age group
- by sex
In the tables and graphics, amounts paid are expressed as percentages (%) of overall spending (or of the demographic segment under analysis). These percentages are also used to assign ranks in order to identify the main cost drivers, the adoption of new treatments, and the dynamics shaping group insurance drug spending.